Pipeline

BioFactura is committed to identifying and fulfilling unmet national biodefense and biomedical needs. Currently, BioFactura is focused on bringing to market a drug for the treatment of smallpox and adverse smallpox vaccination events in collaboration with the U.S. Army and Department of Defense. The Company is evaluating other opportunities in both biodefense and non-biodefense markets.